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Abstract
Purpose The purpose of this study was to investigate what
kind of regulatory affairs tasks is outsourced in the pharma-
ceutical industry and what are the reasons for outsourcing in
the EU countries.
Methods The study was conducted as an e-mail survey in the
pharmaceutical industry in Finland, Sweden, Estonia,
Germany, and Spain, focusing on those companies that under-
take regulatory affairs.
Results The survey received 71 completed responses out of
147, a response rate of 48 %. The most outsourced tasks were
related to translations of product information texts (75 % of
the respondents). The principal reason for outsourcing regula-
tory affairs tasks to a Contract Research Organization (CRO)
was the excessively heavy workload in the company’s regu-
latory affairs. Also, outsourcing should be cost-effective. The
fact that the CRO has experience and knowledge was seen as a
very important requirement when choosing the CRO partner.
Personal, individual contacts were mentioned in many of the
open-ended responses as an essential criterion in the selection
of the CRO.
Conclusions This survey indicated that outsourcing in regu-
latory affairs will continue. The quality of the CRO has a
significant role when the companies select their partner. The
CRO has to assure uniform quality of their personnel knowl-
edge and skills in regulatory affairs, i.e., when the person in
charge of the outsourced task changes in the CRO. Practically
all product development steps can be outsourced by hiring
local and multinational CROs. The companies should plan
the outsourcing carefully and compare possible CROs even
if the company has no plans to outsource at present.
Keywords CRO . Pharmaceutical industry . Regulatory
affairs . Outsourcing
Introduction
The pharmaceutical industry has a long tradition in
outsourcing. About 30 years ago, the outsourcing strategy
was adopted to formulation, clinical trials, and registration.
In the last 10 years, outsourcing has expanded to include most
development and registration processes. Outsourcing has been
practiced where capacity and specialist techniques and know-
how are required. Pharmaceutical research, development, and
manufacturing processes as well as quality control can and are
the subject of regular outsourcing from the largest to the
smallest of pharmaceutical companies [5].
According to Piachaud [16], the increasing proportion of
pharmaceutical R&D being outsourced would drive future
growth of the Contract Research Organization (CRO) sector
by 10–12 %. A recent study by Cutting Edge Information in
the USA [6] shows that outsourcing has become more com-
mon for regulatory affairs tasks. This study found that the top
50 pharmaceutical companies have increased their regulatory
affairs budgets by an average of 27 % during the years 2010–
2012. The percentage of outsourcing regulatory affairs bud-
gets in pharmaceutical companies had increased to 68 %.
According to Cutting Edge Information, small drug
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manufacturers, as well as medical device companies, also con-
currently increased their regulatory affairs budgets. Top 20 phar-
maceutical companies reported that outsourcing consumes ap-
proximately 10 % of the overall regulatory affairs budget. In
order to utilize resources more efficiently in an increasingly com-
petitive environment, the pharmaceutical industry is outsourcing
a large volume of drug development activities toCROs. From the
global perspective, the companies have started to use India and
China as the most popular offshore locations in the past 3 or
4 years [7, 18, 19]. On the other hand, domestic outsourcing is
a fast-emerging strategy among US firms. It means that the
outsourcing is returned to the USA and is performed by the
company or its strategic alliance [15].
There are two main models to outsource pharmaceutical
processes. Strategic outsourcing enables pharmaceutical com-
panies to focus on their core strengths and long-term goals. By
outsourcing in this way, companies aim to maintain high-level
expertise and to reduce the number of internal staff involved in
those processes that are outsourced. As a result, strategic part-
nerships between a company and a CRO can offer the com-
pany an opportunity to have more flexible internal resources.
Strategic outsourcing also provides expertise, competency, or
resources that the companymay not otherwise have. The CRO
has to be selected carefully because the service sector and
quality of CROs can vary depending on what services are
needed and what are the cultural aspects. If the collaboration
is successful, there may be a shift from capacity- to
competence-based outsourcing. According to Clemens [3], a
lot of pharmaceutical companies currently focus on only a few
full-service CROs within a strategic partner-based relation-
ship. The company’s workload is hereby optimized, and the
internal resources can focus on assuring the overall perfor-
mance of the CRO.
Tactical outsourcing, which means contracting out work
on a project-by-project basis, is often related to short-term
projects. These projects cannot be handled internally due to
a lack of internal capacity or resources allowing streamlining
processes. According to the literature review [3, 8, 11, 12],
this model is fading, but apparently not all outsourcing is
strategic; contracts of both models continue to be employed
relative to the company’s specific requirements and
outsourcing strategy. Companies see themselves as taking a
more strategic, rather than tactical, or case-by-case, project-
to-project approach to outsourcing with most planning to
continue this approach. Preferred CRO lists have become
important for a large percentage of respondents; roughly
45 % of company respondents say that more than half of
their outsourcing budget currently goes to preferred CROs in
the year 2014 [4] (Table 1).
Prior research has shown that the outsourced [16–18]
and backsourced tasks [9, 20] in the pharmaceutical in-
dustry have been widely studied. Research on outsourcing
in the pharmaceutical industry has focused mainly on the
economic benefits of the practice [1]. According to the
literature review, the outsourced tasks of preclinical, clin-
ical, manufacturing, and quality control activities have
been studied, while the utilization of CROs in performing
regulatory activities has been of less common interest [2].
Outsourcing of regulatory affairs is still a growing trend.
Regulatory intelligence is a critical part of the success of
the pharmaceutical development process. If the company
or the CRO is unable to define the most suitable regula-
tory affairs process and the correct documentation, mar-
keting authorization for the product can be delayed sig-
nificantly. Therefore, it is useful to study, by scientific
research, what regulatory affairs tasks have been
outsourced and what are the service requirements for a
CRO. Regulatory affairs services can range from simple
tasks to very complex projects involving detailed consul-
tation with relevant guidelines and/or concerned health
agencies. As for the decentralized and mutual recognition
procedures, outsourcing certain assessment activities and
using expert networks among the agencies in a more flex-
ible way could improve the use of resources [13].
A few common models for outsourcing regulatory affairs
services are as follows:
1. Personnel augmentation for expanding current capacity to
meet short-term business needs. The company can rent staff
in-house from CRO. This model helps the company by
Table 1 Examples of strategic and tactical outsourcing of regulatory affairs
Tactical Strategic
✓Writing and reviewing of pharmaceutical-chemical documentation ✓ Regulatory intelligence
✓ eRegulatory intelligence
✓ Preparation and compilation of marketing authorization documentation ✓ Regulatory maintenance of marketing authorization on
behalf of marketing authorization holder
✓ Preparation and compilation of active master files ✓ Coordination of global submissions
✓ SOP writing and training concerning regulatory issues ✓ Regulatory authority liaison (e.g., regulatory consultation within
the company, scientific advice meeting with the authorities)
Modified from Miller [12]
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allowing its core resources to concentrate more on new devel-
opments and regulatory strategies across the development
pipeline.
2. Project-based outsourcing is a task-oriented activity where
outsourcing is limited to specific tasks. Companies may out-
source a particular project. CRO takes control of the
outsourced activity and becomes responsible for its success.
Examples could be a compliance project such as consistency
between national summary of product characteristics and core
company safety information or manufacturing and compli-
ance information in national dossiers versus what the
manufacturing site does.
3. Full-service submission outsourcing, which is suitable for
post-marketing activities such as variations, PSURs, annual
reports, and renewals.
4. Functional submissions, which are applicable for pre-
marketing submissions for clinical trial applications, market-
ing authorization applications, new drug applications, abbre-
viated new drug applications, and different marketing autho-
rization procedures such as mutual recognition, decentralized,
and centralized procedures.
The purpose of this study was to investigate what kind
of regulatory affairs tasks the pharmaceutical industry
outsources and what are the reasons for the outsourcing
in five EU countries.
Methods
The study was performed as an e-mail survey in the pharma-
ceutical industry in Finland, Sweden, Estonia, Germany, and
Spain, focusing on those companies that undertake regulatory
affairs. The countries concerned were selected in order to rep-
resent different European Union countries: Finland and
Sweden are Nordic countries, Estonia joined the EU in
2004, while Germany and Spain are big economies in the
EU. There are also cultural differences between the north
and south parts of the EU, which gives greater variety to the
countries chosen for this study.
The survey was designed to cover the main questions re-
lating to the present outsourcing situation and the reasons,
advantages, disadvantages, and future of outsourcing of regu-
latory affairs. Some of the questions were emphasized by
Piachaud’s study of outsourcing in the pharmaceutical
manufacturing process, which was performed in 2002 [16].
Piachaud’s study was conducted among the pharmaceutical
industry, and some of the questions were also appropriate for
this study. The survey consisted of structured questions, and
where applicable, an open field was included to allow the
respondents to indicate issues that were not included in the
structured question. In addition, space was made available for
open responses/comments at the end of the survey. Some of
the questions were designed so that the respondent was able to
select multiple options. Anonymity was required due to the
confidentiality issues relating to the pharmaceutical industry.
Therefore, the anonymity of the respondents was also assured
in this questionnaire. For quantitative analysis of the re-
sponses, multiple-choice responses were categorized on a
five-point Likert scale. A Bno-opinion^ option was added to
ensure that Bneutral^was not selected for no-opinion answers.
These no-opinion answers were not taken to account when
calculating the average value.
To assure face validity of the questionnaire, a pilot survey
was conducted in late 2010. The pilot survey was sent to five
academic and/or industrial experts. The responses of the pilot
study were not included in the results of the final study. Two
comments were received concerning the linguistic form of the
questionnaire. After making the suggested changes to the con-
tent of the questionnaire, the main phase on the survey started
in March 2011 and ended in August 2011. The list of
responding pharmaceutical companies was provided by
Pharma Industry Finland. The corresponding organizations
from Sweden, Estonia, Spain, and Germany provided their
regulatory affairs contact list. Generic Medicines Association
Finland also provided their regulatory affairs contact list. The
companies represented all sorts of companies: innovation
based and generic companies, large, international companies,
subsidiaries, CROs, CMOs, and small/medium-sized stand-
alone companies. If the regulatory affairs director or manager
or a person of similar authority was not known, the question-
naire was sent to the quality or clinical manager or a person of
similar authority. The questionnaire was sent to one person in
each company. The responding to the survey was done elec-
tronically via Helsinki University E-survey tool. The results
were analyzed with SPSS and transferred to Excel software
for quantitative analysis. The results are presented as percent-
ages and frequencies. Responses to the open-ended questions
were content analyzed by grouping similar themes and ideas
[14]. Some representative responses are referred to in the
BResults^ section.
Results
In total, the survey received 71 completed responses out of
147 questionnaires sent, giving a response rate of 48 %. The
majority (59 out of 147) of responses were received from
Finland and Sweden (Table 2).
The response rate in Estonia was poor, 9 %, although the
questionnaire was sent three times. When the results were
studied closely, there was no difference if the respondent
was from Finland, Sweden, or other countries. For this reason,
results from different countries were combined.
Most of the respondents (80 %) worked in a subsidiary of a
worldwide, international company. This reflects the fact that
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there are not many headquarters located in the countries in-
volved in this survey. Moreover, 64 % of the companies that
responded had proprietary products for human use (85 % hu-
man medicines). Many of the respondent companies also dealt
with medical devices (48 %).
Most commonly, the responder was a person with the title
Bhead of the regulatory affairs^ (62 % of the respondents), but
there were also several other titles, e.g., regulatory affairs
manager or similar (22 %), head of the company (5 %), and
other titles (10 %), such as head of quality assurance, senior
regulatory manager, responsible pharmacist, vice president or
clinical development, and regional regulatory affairs head.
The questionnaire reached well the persons in charge of the
company’s regulatory affairs functions although the titles de-
pend on the organizational structure of the company.
The Reasons for Outsourcing
The principal reason for outsourcing the regulatory affairs
tasks to a CRO was too heavy workload in the company’s
regulatory affairs (strongly agree 55 %) (Table 3).
Too heavy workload can be caused by companies’ strategic
and/or tactical outsourcing decision. The fluctuation of the
workload is difficult to estimate. One comment to the open-
ended field expressed that Bthe management of the company
has a lack of knowledge whereas on the low level the em-
ployees have too heavy workload periodically.^
Naturally, the outsourcing should be cost-effective, and this
was also a finding of this study (27%). This study did not take
a stand on actual costs, but the companies expect to gain
financial benefit from outsourcing.
The strategic decision of a company to outsource regulato-
ry affairs was not seen as an important reason to outsource
regulatory affairs tasks. The companies have in-house knowl-
edge of regulatory affairs, but country-specific expertise is
desired. One open-ended outlined what really is required from
CROs: Bhelping in product text translations for variation
applications.^
Criteria for Selection of CRO
Big pharmaceutical companies need CROs in situations in-
volving lack of resources, whereas smaller companies are de-
pendent on the overall know-how of the CRO, which can
provide more general help in addition to the acquired specific
service. The requirements of the CROwere defined according
to CRO’s experience and knowledge, size of CRO, cost-effec-
tiveness, location, how well it is known, recommendation,
eSubmission tools, and partnership network (Fig. 1).
The fact that CRO has experience and knowledge was seen
as a very important requirement (98%) when choosing a CRO
partner. It was also asked if the size or location of CRO was a
significant issue, but the respondents did not see this as im-
portant. According to the responses, it was not relevant if the
CRO had eCTD database or if CRO had a global partnership
network. The recommendation of CRO from other pharma-
ceutical company was acknowledged. The selection of the
CRO was based on recommendations (80 %) or the prestige
of the CRO (69%). The companies searched for CROs also on
the internet, but only 28% of the respondents answered this to
be common practice. Moreover, 10 % of the respondents re-
ported that they collect information about CROs at exhibitions
and/or congresses.
The open-ended responses revealed that the headquarters
of international pharmaceutical companies evaluate the CROs
and also choose the local CROs. If the selection is done at
local subsidiary level, personal contacts from common profes-
sional history or the company’s own CRO network are used.
The personal, individual contacts were mentioned in many of
the open-ended responses as important criteria for the selec-
tion of the CRO. Responses received from Finland specifical-
ly mentioned that workforce with regulatory affairs skills is
Table 2 Location of the pharmaceutical companies responding to the
survey (n=71)
Country Number of sent
questionnaires (n)
Responses
received (n)
Response
rate (%)
Finland 46 29 63
Sweden 64 30 47
Estonia 22 3 9
Spain 6 4 67
Germany 9 5 55
Total 147 71
Table 3 The reasons for outsourcing (mean, 1=strongly disagree, 5=strongly agree)
Reasons for the outsourcing of the regulatory affairs Likert rating (1–5) (mean value) Standard deviation
Too heavy workload in the regulatory affairs department of the company 4.4 0.9
Cost-effectiveness 2.8 1.2
Company’s strategic decision to outsource the regulatory affairs 2.6 1.4
Company has not enough knowledge of the regulatory affairs 2.1 1.3
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Beasy to get because there are only three professional CRO
companies in Finland.^
Given that the pharmaceutical industry is a highly regulated
sector, it was not surprising that one respondent pointed out
that Bit is hard to find a CRO that would take full regulatory
responsibility of a product; sometimes it easier to do it your-
self than explain.^ This may also express a concern over the
outsourcing partner involved and their qualities, or lack of
them, such as ability and trustworthiness.
The Outsourced Regulatory Tasks
The most outsourced tasks were related to the translations of
the product information texts. CROs have local language ex-
pertise for translating summaries of product characteristics
(SmPC) and package leaflets (PLs), along with labeling texts
(Fig. 2). Many of the international companies do not have
their own subsidiary in the country or do not have translation
capabilities, and therefore, a local contact is required. The
outsourced translation procedure also helps reduce the work-
load in the company because CRO experts are used to trans-
late the medicinal product information texts. This reduces the
time spent on translation.
Related to the translations, almost half of the respondents
reported that the readability testing of the PL has been
outsourced to CROs. The readability test has to be done in a
local language, and in these cases, a local CRO can conduct
the user test. These tests are needed not only mostly for the
new marketing authorization applications but also in case of
extensive variation application concerning the product infor-
mation texts.
As companies want to concentrate on core functions and
new marketing authorization procedures, 44 % of the respon-
dent companies have outsourced the regulatory maintenance
of marketing authorizations, i.e., full-service submission.
CROs have full responsibility of regulatory maintenance of
the products. The companies outsource submissions of the
variation types I (40 %) and II (44 %) to CROs but prepare
the renewals and notifications themselves. One fifth
responded that they have outsourced the process of a new
marketing authorization application in the decentralized/
mutual recognition procedure.
In some cases, it is more practical that the regulatory affairs
expert from the CROworks inside the company. One fourth of
the companies have used this kind of service. The expert in-
side the company has to have a wide experience to adopt the
company’s standard operation procedures in order to handle
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the outsourced work. This work may also contain duties that
are not related to regulatory affairs but, e.g., to
pharmacovigilance and marketing.
Other mentioned outsourced tasks consisted of harmoniza-
tion of module 3 of the Common Technical Document (CTD
structure), catalogue updates, especially in Nordic countries,
and preparation of clinical trial applications.
The Future of Outsourcing Regulatory Affairs Tasks
The outsourcing of the regulatory affairs tasks will continue as
84 % of the respondents said that they will outsource in the
future. The services to be outsourced will be the same kind as
mentioned earlier, but the regulatory maintenance for the
products and new market authorization applications are also
planned to be outsourced more than previously. According to
the open-ended questions, two of the companies have not
planned the outsourcing of the regulatory affairs tasks at any
point but did respond that Bin case of heavy workload
outsourcing could be used.^ Seven of the companies replied
that they have already outsourced regulatory affairs tasks to a
CRO and will continue to outsource similar tasks as previous-
ly. The outsourcing of readability testing for PLs was also
mentioned by two companies. According to the responses,
62 % found that there are enough CROs to which regulatory
affairs tasks can be outsourced.
Discussion
This survey was successful in giving a cross section of
outsourcing regulatory affairs in the EU even though the sur-
vey respondents weremainly from the Nordic countries. In the
concerned countries, companies need local contacts especially
for translations. The tendency of outsourcing regulatory af-
fairs seems to continue, but there are some references also
from backsourcing tasks to companies. According to this sur-
vey, the pharmaceutical companies will outsource full-service
submissions, i.e., post-marketing activities such as preparation
and compilation of the variation applications, PSURs, annual
reports, and renewals. The companies will focus on core func-
tions and new marketing authorization procedures internally
and coordinate these processes by themselves. The selection
of the CRO is based on recommendation or the fact that the
CRO is well known in the pharmaceutical industry. If the
company does not have any collaboration with CROs or rec-
ommendations, they will search for information on the
Internet. In some cases, the headquarters of the international
pharmaceutical companies evaluate the CROs and also choose
the local CROs. If the selection is done at local subsidiary
level, personal contacts from common professional history
or the company’s own CRO network are used. It could be
useful to repeat this survey regularly to see what are the chro-
nological tendencies within the outsourcing.
Generally, and based on this study, CROs have to be con-
scious that the quality control of regulatory affairs tasks has to
be in order to ensure the quality, safety, and efficient use of
medicines and also to keep the customers satisfied. A compet-
itive CRO with quality control points and standard operation
procedure can gain a competitive edge over other CROs.
CROs have to be in the forefront when regulatory affairs
topics are discussed in order to achieve the expertise required.
Before the CRO places their regulatory affairs expert in the
company, the expert has to be trained by the CRO to handle
the various predefined regulatory affairs tasks. Open-ended
questions revealed that there are Bindividual differences be-
tween the hired employees.^ One comment suggested that the
experts should have knowledge Bfrom translations to FDA
specialist knowledge.^ It seems that CRO experience is de-
pendent on individual experience rather than the CRO per se.
The clear scheme for training the personnel to perform possi-
ble tasks inside the company ensures that CRO provides good
quality even if the employee has to be replaced during the
agreement period.
The translation of texts also requires standard operation
procedures from the CRO on the quality control of the trans-
lations. CROs might have their own translators, or they have a
network for the translation procedure for different languages.
The CRO has to have a strong and long-term expertise to
perform the readability tests for PLs. Strong expertise is need-
ed according to the study of Maat et al., which found that the
leaflets were not user-friendly and contained problems related
to finding relevant information [10]. The CRO is in a key role
in proposing possible changes to the PLs.
The CRO has to be aware of the tight timelines for the
tasks. The company often informs the CRO of the work tasks
very close to the deadline. This is due the fact that the final
decision dates informed by the authorities are not known or
that the authorities can make changes for instance to the prod-
uct information texts before the final decision. The responsi-
bilities should be clearly defined when preparing the agree-
ment between the company and the CRO. The timelines for
the various tasks should also be specified to avoid the discrep-
ancies between the expectations and realizations of the work
tasks. This is very crucial, for instance, when there is an agree-
ment for the translation procedures of the product information
texts.
Referring to companies strategic decisions to outsource, it
is essential that all sourcing decisions support the organiza-
tion’s overall business strategy and are revised accordingly as
competitive conditions change [16]. According to the re-
sponses, it is essential that the personnel is informed and up-
dated of the company’s outsourcing strategy. Based on this
study, the outsourcing decisions or the strategic decisions
were not clearly informed to company’s personnel. If the
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company’s management does not have enough knowledge
about the requirements and time-consuming tasks of regulato-
ry affairs, the company has problems taking care of the regu-
latory affairs tasks without transferring these extra tasks to a
third party. This might also reflect the relationships at a prac-
tical level when the company and the CRO personnel discuss
the outsourcing of the tasks. This might lead to a rapid turn-
over of the company’s or CRO’s skilled employees to seek for
jobs in companies where communication and strategies are
more clear. The employees have to be treated respectfully,
fairly, and equal in accordance with laws and culture. It is also
necessary to create an environment that supports the develop-
ment and well-being of every employee.
When the company plans for the outsourcing, the selection
of CRO has to be done carefully. Outsourcing support services
help companies become more efficient, have access to new
skills and resources, and focus on the core business. Before
selecting a CRO, the company has to define what tasks will be
outsourced and to what extent the outsourcing will be done.
The CRO that is chosen can be located in a different town or
even country than the company itself, but it is practical if the
CRO has local expertise in the country that is concerned.
Problems in local language also trigger outsourcing of regu-
latory affairs tasks. The companies themselves want to focus
on regulatory affairs strategies of their high priority products.
Conclusion
This survey indicated that the outsourcing in the regulatory
affairs is common and will continue. Most of the companies in
the EU have already outsourced these tasks to CROs. The
quality of the CRO has a significant role when selecting the
CRO. The CRO has to assure uniform quality of their person-
nel’s regulatory affairs knowledge and skills, i.e., when the
CRO regulatory affairs person changes in the outsourced task.
Practically all product development steps can be outsourced
by hiring local and multinational CROs. The companies
should plan the outsourcing carefully and compare CROs
even if the company has no plans to outsource at present.
When planning and preparation has been done thoroughly,
the outsourcing procedure is fluent and the responsibilities
and responsibility issues are known without doubt.
There is some indication that pharmaceutical companies
may be commencing to take back development activities in-
house because of the difficulties in managing outsourced in-
novation processes. The follow-up and control of outsourcing
costs need to be studied more precisely in the future.
According to the literature review, cost evaluation research
in outsourcing of regulatory affairs has not been done. One
important area for further research is the question of how
moral responsibility is assigned in CROs. In some cases, there
appears to be a clear disconnection between CROs and their
clients when it comes to who should take responsibility when
a failure is detected.
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